In conclusion, our data suggest that NKX3-2 represents a negative prognostic marker and may provide the basis for the identification of a molecular signature capable of predicting the clinical outcome of ovarian cancer patients, a crucial aspect for the development of a more effective therapeutic approach. The gene discussed is NKX3-2; the disease is ovarian carcinoma.